Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores.

Niemann CU, Behrends M, Quan D, Eilers H, Gropper MA, Roberts JP, Hirose R.

Transfus Med. 2006 Apr;16(2):93-100.

PMID:
16623915
2.

Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.

Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas JC, McAlister V, Mirza DF; rFVIIa OLT Study Group.

Liver Transpl. 2005 Aug;11(8):973-9.

3.

Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study.

Hendriks HG, Meijer K, de Wolf JT, Klompmaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Slooff MJ, van der Meer J.

Transplantation. 2001 Feb 15;71(3):402-5.

PMID:
11233901
4.

Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease.

Planinsic RM, van der Meer J, Testa G, Grande L, Candela A, Porte RJ, Ghobrial RM, Isoniemi H, Schelde PB, Erhardtsen E, Klintmalm G, Emre S.

Liver Transpl. 2005 Aug;11(8):895-900.

5.

Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.

Perkins JG, Schreiber MA, Wade CE, Holcomb JB.

J Trauma. 2007 May;62(5):1095-9; discussion 1099-101.

PMID:
17495707
6.

Methods to decrease blood loss and transfusion requirements for liver transplantation.

Gurusamy KS, Pissanou T, Pikhart H, Vaughan J, Burroughs AK, Davidson BR.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009052. doi: 10.1002/14651858.CD009052.pub2. Review.

PMID:
22161443
7.

Recombinant activated factor VII in patients with acute liver failure with UNOS Status 1A: a single tertiary academic centre experience.

Pham HP, Hsu SX, Parker-Jones S, Samstein B, Diuguid D, Schwartz J.

Vox Sang. 2014 Jan;106(1):75-82. doi: 10.1111/vox.12067. Epub 2013 Jul 1.

PMID:
23815226
8.

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.

Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG.

Liver Transpl. 2003 Feb;9(2):138-43.

9.

Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.

Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF.

Transfusion. 2013 Apr;53(4):798-804. doi: 10.1111/j.1537-2995.2012.03801.x. Epub 2012 Jul 31.

PMID:
22845023
10.

Use of recombinant activated factor VII concentrate to control postoperative hemorrhage in complex cardiovascular surgery.

Bowman LJ, Uber WE, Stroud MR, Christiansen LR, Lazarchick J, Crumbley AJ 3rd, Kratz JM, Toole JM, Crawford FA Jr, Ikonomidis JS.

Ann Thorac Surg. 2008 May;85(5):1669-76; discussion 1676-7. doi: 10.1016/j.athoracsur.2008.01.089.

PMID:
18442563
11.

Recombinant activated factor VII in critical bleeding after orthotopic liver transplantation.

Busani S, Semeraro G, Cantaroni C, Masetti M, Marietta M, Girardis M.

Transplant Proc. 2008 Jul-Aug;40(6):1989-90. doi: 10.1016/j.transproceed.2008.05.021.

PMID:
18675109
13.

Recombinant activated factor VII in spinal surgery: a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial.

Sachs B, Delacy D, Green J, Graham RS, Ramsay J, Kreisler N, Kruse P, Khutoryansky N, Hu SS.

Spine (Phila Pa 1976). 2007 Oct 1;32(21):2285-93.

PMID:
17906567
14.

Preemptive administration of recombinant factor VII (rVIIa) in patients transplanted due to fulminant Wilson's disease.

Czuprynska MM, Wawrzynowicz-Syczewska M, Jureczko L, Andrzejewska J, Jarosz K, Trzebicki J, Pacholczyk M, Chmura A, Wojcicki M.

Ann Transplant. 2010 Jul-Sep;15(3):7-10.

PMID:
20877260
15.
16.

Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): a propensity score analysis.

Gelsomino S, Lorusso R, Romagnoli S, Bevilacqua S, De Cicco G, Billè G, Stefàno P, Gensini GF.

Eur J Cardiothorac Surg. 2008 Jan;33(1):64-71. Epub 2007 Nov 8.

PMID:
17996457
17.

Use of recombinant factor VIIa for uncontrolled bleeding in neonates after cardiopulmonary bypass.

Guzzetta NA, Huch S, Fernandez JD, Tosone SR, Miller BE.

Paediatr Anaesth. 2009 Apr;19(4):364-70. doi: 10.1111/j.1460-9592.2008.02905.x. Epub 2008 Dec 30.

PMID:
19143947
18.

The clinical and laboratory response to recombinant factor VIIA in trauma and surgical patients with acquired coagulopathy.

McMullin NR, Kauvar DS, Currier HM, Baskin TW, Pusateri AE, Holcomb JB.

Curr Surg. 2006 Jul-Aug;63(4):246-51.

PMID:
16843774
19.

Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients.

Brown CV, Foulkrod KH, Lopez D, Stokes J, Villareal J, Foarde K, Curry E, Coopwood B.

J Trauma. 2010 Feb;68(2):348-52. doi: 10.1097/TA.0b013e3181bbfb6b.

PMID:
20154547
20.

Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.

von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, Grosse J, Ziemer S, Koscielny J, Konertz WF, Wernecke KD, Spies C.

Crit Care Med. 2005 Oct;33(10):2241-6.

PMID:
16215377

Supplemental Content

Support Center